Telomere assay for the detection of alternative lengthening of telomere (ALT) activity in cells

Overview

Executive Statement:

A unique tool for distinguishing cancer cells based on telomere maintenance mechanisms, providing potential biomarkers for cancer subtypes and therapeutic responses.

Description:

This technology provides detailed telomere profiling from individual chromosomes, capable of differentiating Alternative Lengthening of Telomere (ALT+) cancer cells from telomerase (TEL+) cancer cells. This technology identifies unique telomeric profiles and has implications in discerning subtypes of ALT+ cancer and monitoring responses to treatments. This use case can be extended to other disease and cancer type diagnosis and monitoring for cell and gene therapy.

Market Applications

  • Application in cancer research for understanding different types of cancers
  • Useful tool for personalized medicine in cancer treatment
  • Monitoring the effectiveness of cancer treatments in real-time

Key Advantages

  • Allows measurement and analysis of telomere lengths from individual chromosomes
  • Capable of distinguishing between ALT+ and TEL+ cancer cells
  • Identifies unique telomeric profiles in ALT+ cancer cells
  • Can potentially aid in identifying subtypes of ALT+ cancer
  • Useful in monitoring responses to cancer treatments

Problems Solved

  • Lack of tools to differentiate between ALT+ and TEL+ cancer cells based on telomere profiles
  • Difficulty in monitoring responses to cancer treatments at the genomic level

Intellectual Property and Development Status

United States Provisional filed.

References

Genes 2023: Single-Molecule Telomere Assay via Optical Mapping (SMTA-OM) Can Potentially Define the ALT Positivity of Cancer

Commercialization Opportunities

This invention is part of a larger portfolio of technologies available for licensing and commercialization around TOOLS FOR GENOMIC APPLICATIONS POWERED BY CRISPR/CAS9 BASED DNA LABELING 

Contact Information

For Intellectual Property and Licensing inquiries

Tanvi Muni, PhD

Licensing Manager,

Drexel Applied Innovation

Office of Research and Innovation

3250 Chestnut Street, Ste. 3010
Philadelphia, PA 19104

Phone:267-359-5640

Email:tanvi.muni@drexel.edu

Inventor information

Ming Xiao, PhD

Professor
School of Biomedical Engineering, Science and Health Systems

Phone:215-895-2690

Email:mx44@drexel.edu

Inventor Webpage

For Information, Contact:

  • Robert Mcgrath
  • Sr. Associate Vice Provost
  • Drexel University
  • 215-895-0303
  • rbm26@drexel.edu

Inventors:

Keywords: